Title : Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.

Pub. Date : 2021

PMID : 34367186






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib Janus kinase 2 Mus musculus
2 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib Janus kinase 2 Mus musculus
3 Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation. ruxolitinib Janus kinase 2 Mus musculus
4 Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro. ruxolitinib Janus kinase 2 Mus musculus